Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Alexey S RevenkoLarissa S CarnevalliCharles SinclairBen JohnsonAlison PeterMolly TaylorLisa HettrickMelissa ChapmanStephanie KleinAnisha SolankiDanielle GattisAndrew WattAdina M HughesLukasz MagieraGozde KarLucy IrelandDeanna A MeleVasu SahManeesh SinghJosephine WaltonMaelle MairesseMatthew KingMark EdbrookePaul LyneSimon T BarryStephen FawellFrederick W GoldbergA Robert MacLeodPublished in: Journal for immunotherapy of cancer (2022)
Antisense inhibitors of FOXP3 offer a promising novel cancer immunotherapy approach. AZD8701 is being developed clinically as a first-in-class FOXP3 inhibitor for the treatment of cancer currently in Ph1a/b clinical trial (NCT04504669).